Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

By S. Cosgrove, G. Sakoulas, E. Perencevich, M. Schwaber, A. Karchmer, Yehuda Carmeli. Clinical Infectious Diseases, 2003

2,158 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Infectious Diseases, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/87b40e85dff71b55f8b8146bb04a9238f47fca61

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. S. Cosgrove
2. F. Lowy
3. D. Levine
4. H. Boucher
5. M. Billeter
6. G. Corey

In Infectious Diseases

1. T. Dellit
2. Trish Perl
3. Emily R. M. Sydnor
4. Neil O. Fishman
5. S. Cosgrove
6. G. Peters
7. J. Burke
8. F. Lowy

In Public Health, Environmental and Occupational Health

1. T. Dellit
2. Emily R. M. Sydnor
3. Trish Perl
4. S. Cosgrove
5. F. Lowy
6. David L. Paterson

Citations in the corpus

• Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. (2006, result): “However, when the studies were combined in a meta-analysis, the odds ratio for increased mortality from MRSA bacteraemia was statistically significant.(33) There is also significant morbidity and mortality associated with other invasive MRSA infections.”
• The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. (2004, background): “For both treatment groups, success rates for MRSA were lower than for MSSA, most likely reflecting the comorbidities prevalent among these patients [24–27].”
• Antimicrobial resistance: A global emerging threat to public health systems (2017, background): “A study demonstrated that in case of bloodstream infection from MRSA, mortality is two or three times higher than in infection with nonresistant strain (Cosgrove et al., 2003).”
• The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. (2006, methodology): “To further address this issue, we conducted a meta-analysis of studies with relevant mortality data published between 1980 and 2000 [18].”
• Vancomycin: a history. (2006, background): “for increased mortality among patients with MRSA infection [85].”
• Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. (2010, result): “Two meta-analyses have found an increased mortality risk of 1.93 (95% CI: 1.54 to 2.42) [10] and 2.03 (95% CI: 1.55 to 2.65) [11] associated with MRSA bacteraemia compared with MSSA.”
• Antimicrobial resistance: the example of Staphylococcus aureus. (2003, background): “aureus (MRSA) is worse than the outcome of those that result from methicillin-sensitive strains (20).”
• Hospital Epidemiology and Infection Control in Acute-Care Settings (2011, background): “aureus (MSSA), which persists after controlling for the severity of underlying illnesses (77, 92, 299).”
• SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus (2003, neutral): “The same authors conducted a meta-analysis of 31 cohort studies and concluded that MRSA bloodstream infection was significantly more lethal, resulting in almost a doubling of the case fatality rate after adjustment for other predictors such as underlying severity of illness.(15) Cheng et al.”